News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
206,721 Results
Type
Article (4765)
Company Profile (95)
Press Release (201861)
Section
Business (63274)
Career Advice (96)
Deals (12027)
Drug Delivery (3)
Drug Development (34468)
Employer Resources (12)
FDA (3889)
Job Trends (3788)
News (113567)
Policy (8418)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (1)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (2)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (237)
Accelerated approval (1)
Allergies (31)
Alliances (16878)
ALS (33)
Alzheimer's disease (396)
Antibody-drug conjugate (ADC) (40)
Approvals (3955)
Artificial intelligence (45)
Autoimmune disease (7)
Automation (1)
Bankruptcy (56)
Best Places to Work (3237)
BIOSECURE Act (2)
Biosimilars (37)
Biotechnology (66)
Bladder cancer (34)
Brain cancer (13)
Breast cancer (72)
Cancer (751)
Cardiovascular disease (36)
Career advice (88)
Career pathing (2)
CAR-T (45)
Cell therapy (118)
Cervical cancer (3)
Clinical research (29700)
Collaboration (274)
Compensation (283)
Complete response letters (4)
COVID-19 (508)
CRISPR (5)
C-suite (96)
Cystic fibrosis (21)
Data (885)
Depression (12)
Diabetes (65)
Diagnostics (904)
Digital health (1)
Diversity, equity & inclusion (2)
Drug discovery (32)
Drug pricing (2)
Drug shortages (1)
Duchenne muscular dystrophy (26)
Earnings (26803)
Editorial (2)
Employer branding (1)
Employer resources (11)
Events (36583)
Executive appointments (284)
FDA (4315)
Featured Employer (17)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (1)
Funding (190)
Gene editing (13)
Generative AI (1)
Gene therapy (52)
GLP-1 (162)
Government (586)
Grass and pollen (1)
Guidances (15)
Healthcare (2637)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (22)
Indications (13)
Infectious disease (535)
Inflammatory bowel disease (50)
Influenza (11)
Intellectual property (39)
Interviews (12)
IPO (6363)
IRA (2)
Job creations (713)
Job search strategy (82)
Kidney cancer (5)
Layoffs (36)
Legal (1529)
Liver cancer (27)
Lung cancer (122)
Lymphoma (62)
Management (4)
Manufacturing (94)
MASH (35)
Medical device (1402)
Medtech (1403)
Mergers & acquisitions (5938)
Metabolic disorders (188)
Multiple sclerosis (29)
NASH (7)
Neurodegenerative disease (21)
Neuropsychiatric disorders (2)
Neuroscience (569)
NextGen: Class of 2025 (889)
Non-profit (235)
Northern California (1115)
Now hiring (2)
Obesity (85)
Opinion (16)
Ovarian cancer (25)
Pain (24)
Pancreatic cancer (22)
Parkinson's disease (47)
Partnered (2)
Patents (74)
Patient recruitment (42)
Peanut (15)
People (18443)
Pharmaceutical (34)
Phase I (8664)
Phase II (13324)
Phase III (9955)
Pipeline (491)
Policy (7)
Postmarket research (673)
Preclinical (3206)
Press Release (13)
Prostate cancer (26)
Psychedelics (4)
Radiopharmaceuticals (108)
Rare diseases (95)
Real estate (1439)
Recruiting (7)
Regulatory (6922)
Reports (12)
Research institute (269)
Resumes & cover letters (6)
RSV (5)
Schizophrenia (41)
Series A (32)
Series B (23)
Service/supplier (3)
Sickle cell disease (5)
Southern California (899)
Spinal muscular atrophy (40)
Sponsored (3)
Startups (1024)
State (1)
Stomach cancer (1)
Supply chain (15)
Tariffs (3)
United States (8233)
Vaccines (107)
Venture capitalists (3)
Weight loss (15)
Women's health (2)
Date
Today (54)
Last 7 days (294)
Last 30 days (900)
Last 365 days (11972)
2025 (3798)
2024 (12947)
2023 (14943)
2022 (19577)
2021 (20796)
2020 (18161)
2019 (11688)
2018 (8520)
2017 (10598)
2016 (8980)
2015 (11562)
2014 (8764)
2013 (6702)
2012 (6788)
2011 (6907)
2010 (6729)
Location
Africa (135)
Alabama (15)
Arizona (27)
Arkansas (2)
Asia (28050)
Australia (3404)
California (2333)
Canada (628)
China (377)
Colorado (65)
Connecticut (83)
Delaware (77)
Europe (31053)
Florida (282)
Georgia (71)
Idaho (3)
Illinois (98)
India (11)
Indiana (66)
Iowa (2)
Japan (107)
Kansas (57)
Kentucky (7)
Louisiana (1)
Maine (6)
Maryland (245)
Massachusetts (1809)
Michigan (31)
Minnesota (100)
Missouri (13)
Nebraska (5)
Nevada (4)
New Hampshire (2)
New Jersey (894)
New Mexico (4)
New York (815)
North Carolina (342)
Northern California (1115)
Ohio (57)
Oklahoma (3)
Oregon (10)
Pennsylvania (401)
Puerto Rico (1)
Rhode Island (2)
South America (200)
Southern California (899)
Tennessee (8)
Texas (222)
Utah (47)
Virginia (68)
Washington D.C. (10)
Washington State (123)
Wisconsin (12)
206,721 Results for "shenzhen hightide biopharmaceutical ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
ROCKVILLE, MD and SHENZHEN, CHINA, HighTide Therapeutics, Inc. (Stock Code: 2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy.
June 5, 2024
·
4 min read
Press Releases
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
March 5, 2025
·
1 min read
Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Announce Collaboration to Develop Herpes Vaccines in China
Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. announced they have reached an agreement to jointly develop, manufacture, and commercialize live vaccines against herpes simplex viruses.
October 30, 2023
·
2 min read
Press Releases
BioCity Biopharmaceutics Co., Ltd. Announces Clinical Collaboration to Evaluate BC3195 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
March 13, 2025
·
3 min read
Deals
Bowen Acquisition Corp Announces Entering into Merger Agreement with Shenzhen Qianzhi BioTech Company
Bowen Acquisition Corp, a special purpose acquisition company, announced the execution of an agreement and plan of merger with Shenzhen Qianzhi BioTechnology Co., Ltd, a biotech company engaged in development, manufacturing and sales of ozonated health and wellness products in China.
January 18, 2024
·
11 min read
Novotech Signs Strategic MOU with Hong Kong-Shenzhen Innovation and Technology Park Limited (HSITPL)
Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.
May 29, 2024
·
4 min read
Press Releases
Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044
January 2, 2025
·
2 min read
Press Releases
Kairos Pharma Ltd. Provides Letter to Stockholders
April 24, 2025
·
5 min read
Press Releases
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments
April 28, 2025
·
10 min read
Press Releases
Tenpoint Therapeutics Ltd. to Participate at Citi Biotech Private Access Day
April 23, 2025
·
1 min read
1 of 20,673
Next
